ENGN ENGN
Company Profile ↓Company Overview
ENGN (ENGN) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 0.8.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -52.88% |
| 6 Months: | -81.95% |
| 3 Months: | -77.19% |
| 1 Month: | -6.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)44.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 85.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2023 | Apr 2023 | Jul 2023 | Jan 2024 | Apr 2024 | Jul 2024 | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 27.12M | 29.95M | 39.48M | 31.18M | 31.97M |
| Operating Income | -4.63M | -4.74M | -6.25M | -10.77M | -17.31M | -16.76M | - | -27.12M | -29.95M | -39.48M | -31.18M | -31.97M |
| EBITDA | - | - | - | - | - | - | - | -24.73M | -27.86M | -37.46M | -28.83M | -29.30M |
| Interest Expense | - | - | - | - | - | - | - | 734.00K | 758.00K | 750.00K | 732.00K | 745.00K |
| Pretax Income | - | - | - | - | - | - | - | -25.57M | -28.75M | -38.38M | -29.75M | -30.23M |
| Tax Provision | - | - | - | - | - | - | - | 240.00K | 239.00K | -497.00K | 0 | 0 |
| Net Income | -7.42M | -5.28M | -4.72M | -10.71M | -14.98M | -14.15M | - | -25.82M | -28.99M | -37.88M | -29.75M | -30.23M |
| Diluted EPS | 13.29 | 9.30 | 8.55 | 0.46 | 0.38 | 0.32 | -0.48 | -0.51 | -0.57 | - | -0.44 | -0.43 |
| R&D Expense | 3.67M | 3.21M | 3.90M | 5.64M | 9.86M | 11.55M | 19.97M | 20.21M | 22.57M | - | 22.25M | 22.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|
| Operating Income | -19.43M | -26.06M | -62.30M | -123.17M |
| Net Income | -24.46M | -99.92M | -55.14M | -117.30M |
| Diluted EPS | 44.30 | 151.22 | 1.46 | 2.29 |
| R&D Expense | 15.47M | 16.46M | 38.31M | 94.48M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 23.91M | 86.96M | 311.17M | 221.47M |
| Total Equity | -53.44M | -76.61M | 72.49M | 272.61M | 167.71M |
| Cash & Equivalents | - | 20.43M | 81.52M | 173.00M | 50.15M |
| Total Liabilities | - | 47.41M | 14.47M | 38.56M | 53.76M |
| Current Liabilities | - | 5.10M | 5.26M | 14.66M | 31.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -17.59M | -24.74M | -48.28M | -99.24M |
| Investing Cash Flow | -153.00K | -318.00K | -125.95M | -25.14M |
| Financing Cash Flow | 27.97M | 86.15M | 265.72M | 1.52M |
| Capital Expenditure | -153.00K | -318.00K | -925.00K | -1.49M |
| Free Cash Flow | -17.75M | -25.06M | -49.21M | -100.72M |
| Dividends Paid | - | 0 | - | - |
Ratios (Annual)
Figures in %.
| Metric | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 31.9% | -137.8% | -20.2% | -69.9% |
| ROCE % | -103.3% | -31.9% | -21.0% | -65.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ENGN
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
BOSTON & MONTREAL, August 04, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tue…
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
BOSTON & MONTREAL, July 16, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulat…
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.Rectify is developing oral medicines designed to rectify…
Neumora depression drug fails; EnGene to cut 50% of staff
Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.
A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations
Why enGene Therapeutics stock is suddenly on investors’ radar enGene Therapeutics (ENGN) is in the spotlight after updated interim data from its Phase 2 LEGEND trial in high risk, BCG unresponsive non muscle invasive bladder cancer, followe…
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
enGene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk BCG-unresponsive non-muscle invasive bladder canc…
ENGN — Frequently Asked Questions
What is the current share price of ENGN?
As of 2026-08-05 17:25 PDT, ENGN trades at $1.80 on NASDAQ/NYSE. Its 52-week range is $1.44 to $12.17.
What is the P/E ratio of ENGN?
ENGN trades at a trailing price-to-earnings (P/E) ratio of 0.79.
What is the return on equity (ROE) of ENGN?
ENGN has a return on equity (ROE) of -69.94%. Its return on capital employed (ROCE) is -65.00%.
Is ENGN a good stock to buy?
This page provides a data-driven analysis of ENGN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.